Cargando…

Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer

SIMPLE SUMMARY: The aim of the study was to investigate the efficacy of irinotecan-releasing beads in the treatment of metastatic colorectal cancer after prior cetuximab monotherapy in patients with metastatic colorectal cancer, as it has been suggested that the development of resistance to anti-EGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szemitko, Marcin, Golubinska-Szemitko, Elzbieta, Sienko, Jerzy, Falkowski, Aleksander, Wiernicki, Ireneusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856261/ https://www.ncbi.nlm.nih.gov/pubmed/36672489 http://dx.doi.org/10.3390/cancers15020541

Ejemplares similares

Complications Following Irinotecan-Loaded Microsphere Chemoembolization of Colorectal Metastatic Liver Lesions Associated with Hepatic-Artery Branch Temporary Stasis
por: Szemitko, Marcin, et al.
Publicado: (2021)

Side Effect/Complication Risk Related to Injection Branch Level of Chemoembolization in Treatment of Metastatic Liver Lesions from Colorectal Cancer
por: Szemitko, Marcin, et al.
Publicado: (2020)

Evaluation of CRC-Metastatic Hepatic Lesion Chemoembolization with Irinotecan-Loaded Microspheres, According to the Site of Embolization
por: Szemitko, Marcin, et al.
Publicado: (2022)

Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD
por: Falkowski, Aleksander, et al.
Publicado: (2020)

Utility of Diagnostic Imaging in the Early Detection and Management of the Fournier Gangrene
por: Sumisławski, Piotr, et al.
Publicado: (2022)

The Impact of the COVID-19 Epidemic on the Mood and Diet of Patients Undergoing Bariatric Surgery
por: Boniecka, Iwona, et al.
Publicado: (2022)

Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report
por: MEKATA, EIJI, et al.
Publicado: (2013)

Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
por: Tanioka, Hiroaki, et al.
Publicado: (2018)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
por: Sato, Yasuyoshi, et al.
Publicado: (2015)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer
por: Inoue, Yuka, et al.
Publicado: (2017)

Optic Pathway Gliomas in Pediatric Population—Current Approach in Diagnosis and Management: Literature Review
por: Modrzejewska, Monika, et al.
Publicado: (2023)

Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis
por: Neyns, B., et al.
Publicado: (2008)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight
por: Peddi, Prakash, et al.
Publicado: (2016)

Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer
por: Chen, Baomin, et al.
Publicado: (2020)

Initial experience with novel Embocure Plus microspheres for transarterial chemoembolization (TACE) of liver metastatic colorectal cancer tumours – a clinical and in vitro study
por: Piasecki, Piotr, et al.
Publicado: (2021)

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy
por: Price, Timothy, et al.
Publicado: (2020)

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
por: Jehn, C F, et al.
Publicado: (2012)

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
por: Goldberg, Richard M, et al.
Publicado: (2018)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
por: Wang, Haohua, et al.
Publicado: (2018)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?
por: Benkö, Tamás, et al.
Publicado: (2022)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
por: Tintelnot, Joseph, et al.
Publicado: (2022)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Prediction of Complete Necrosis of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Prior to Liver Transplantation
por: Kim, Sue Jin, et al.
Publicado: (2009)

Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study
por: Feng, Qingyang, et al.
Publicado: (2016)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
por: Pfeiffer, Per, et al.
Publicado: (2009)

Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market
por: Davari, Majid, et al.
Publicado: (2015)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab
por: GHERMAN, ALEXANDRA, et al.
Publicado: (2017)

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
por: Baas, J. M., et al.
Publicado: (2015)

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
por: Volz, Nico B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_31c4qps5ude19go422v8qmaf4j